VIVUS is a biopharmaceutical company committed to advancing innovative clinical therapies. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. VIVUS manufactures Qsymia® (phentermine and topiramate extended-release) CIV and PANCREAZE® (pancrelipase) delayed-release capsules.